Tempus AI, Inc.

Tempus AI, Inc. Annual Report: A Deep Dive for Investors

Tempus AI, Inc. stands at the forefront of healthcare innovation, harnessing data and artificial intelligence (AI) to personalize medicine, especially in oncology. The past year proved pivotal, marked by significant strategic expansion and continued investment in its AI-driven platform. For investors, understanding Tempus AI's performance, strategy, and risks is crucial.

Here's a comprehensive look at Tempus AI's year:

1. Business Overview

Tempus AI's core mission is to empower physicians and researchers with data-driven insights. The company achieves this through several integrated offerings:

• Genomics Products: Offers comprehensive genomic sequencing and analysis for various cancers and diseases, guiding treatment decisions.
• Trials Products: Provides AI-powered tools that match patients to clinical trials and analyze data, accelerating enrollment and optimizing research.
• Insights Products: Supplies de-identified, real-world data and analytical tools to pharmaceutical companies, researchers, and healthcare providers, aiding drug discovery and treatment optimization.
• AI Applications: This foundational technology applies advanced machine learning across all product lines, extracting actionable insights from complex healthcare data.
• Data and Applications: Develops robust platforms and tools that integrate vast, multimodal datasets (clinical, genomic, imaging) to create a holistic view of patient health.

Tempus AI operates within a dynamic environment shaped by key trends: the increasing demand for personalized treatments (precision medicine), the broader integration of AI into clinical workflows and drug discovery, and the growing reliance on real-world data for pharmaceutical R&D. These trends provide significant tailwinds for Tempus AI's genomics and AI-driven solutions.

2. Financial Performance

Tempus AI reported $520 million in total revenue for the fiscal year, a 35% increase year-over-year. This growth primarily stemmed from increased adoption of its Genomics Products and expanded data licensing agreements within its Insights segment. Despite strong revenue growth, the company reported a net loss of $185 million, due to substantial investments in research and development (R&D) and strategic acquisitions.

• Cost of Revenues for Diagnostics and Data & Applications segments totaled $195 million, resulting in a gross margin of approximately 62.5%.
• Research and Development Expenses rose 25% to $210 million, highlighting the company's commitment to innovation and AI platform development.
• Selling, General, and Administrative Expenses reached $280 million, reflecting expanded sales efforts and integration costs from recent acquisitions.

3. Risk Factors

Investors should be aware of several key risks that could impact the company's performance and stock price:

• Dilution Risk: Outstanding Convertible Senior Notes and various Warrants (including those related to Allen Company and Pathos) could convert or exercise into common stock. This would increase the total number of shares, potentially diluting the value of existing shares and earnings per share.
• Profitability Challenges: Despite strong revenue growth, Tempus AI has not yet achieved profitability. High R&D and SG&A expenses, coupled with acquisition integration costs, could delay profitability and impact investor sentiment.
• Regulatory and Compliance Risk: Operating in highly regulated healthcare, genomics, and AI sectors, Tempus AI faces ongoing scrutiny from bodies like the FDA and HIPAA. Changes in regulations, or failure to comply, could lead to significant penalties, operational disruptions, or limitations on its products and services.
• Data Privacy and Security: Handling vast amounts of sensitive patient data makes the company vulnerable to cybersecurity breaches. A significant breach could result in substantial financial penalties, reputational damage, and loss of customer trust.
• Integration Risk of Acquisitions: The success of recent acquisitions depends on effective integration. Failure to fully integrate acquired technologies, personnel, or operations could hinder expected synergies and financial benefits.
• Contingent Payment Obligations: Contingent consideration and shares issuable contingently from past acquisitions represent uncertain future financial obligations. If performance milestones are met, these could result in additional cash payments or share issuances, impacting financial flexibility or shareholder dilution.

4. Management Discussion & Analysis Highlights

This past year, Tempus AI achieved robust operational growth, expanding its reach and capabilities. The company made key strategic moves, including acquiring Deep 6 AI (enhancing clinical trial matching), Mpirik (strengthening cardiovascular AI diagnostics), and Sengine (bolstering genomic sequencing capabilities). A significant strategic investment in Ambry Genetics Corporation further solidified its position in clinical genetic testing. Partnerships with industry leaders like AstraZeneca (for precision oncology trials) and Personalis Inc. (for advanced genomic profiling) underscore its collaborative approach. The formation of the SB Tempus Corp joint venture also expanded its global footprint and service offerings. These initiatives collectively positioned Tempus AI for continued leadership in the precision medicine landscape.

Despite strong revenue growth, the company reported a net loss, due to substantial investments in research and development (R&D) and strategic acquisitions. Management's focus remains on capturing market share and scaling its platform, with profitability targeted in the medium to long term. While these strategic acquisitions significantly expanded Tempus AI's technological stack and market reach, the substantial R&D and acquisition-related expenses maintained pressure on profitability. Furthermore, the company carries contingent consideration and holdback liabilities totaling approximately $75 million related to past acquisitions (e.g., Paige, Sengine). They represent potential future cash outflows or share issuances depending on the performance of the acquired entities, adding an element of financial uncertainty. Integrating multiple acquired companies also presents operational complexities and risks to synergy realization.

The leadership team, under CEO Eric D. Belcher, maintained a consistent strategic direction focused on aggressive growth and technological integration. The company's strategy centers on vertical integration, expanding its proprietary data assets, and leveraging AI to drive innovation in precision oncology and broader healthcare applications. This involves continuous investment in R&D, strategic acquisitions to fill technology gaps, and fostering partnerships to expand market reach and clinical utility. Management also closely monitors the evolving regulatory landscape for AI-driven diagnostics and data privacy (e.g., HIPAA, potential new federal data privacy laws), as well as changes in healthcare reimbursement policies for genomic testing and AI-driven diagnostics, as these factors could significantly impact revenue streams and market access.

5. Financial Health

Tempus AI ended the fiscal year with $210 million in cash and cash equivalents. The company's capital structure includes a Term Loan Agreement with Ares Capital Corporation, with an outstanding principal balance of $300 million. The company also holds Convertible Senior Notes totaling $250 million due in 2027. These notes, a form of debt, can convert into company stock under certain conditions, potentially leading to dilution for existing shareholders. To ensure operational flexibility, Tempus AI has access to an undrawn $100 million Revolving Credit Facility, providing additional liquidity as needed. While debt levels are manageable given its growth trajectory, continued investment in R&D and potential future acquisitions will require careful capital management.

6. Future Outlook

Tempus AI expects continued expansion, planning to further scale its AI platform and expand its product offerings into new disease areas beyond oncology. The company anticipates launching two new AI-driven diagnostic tools in the coming fiscal year. To support this growth and ongoing R&D, Tempus AI initiated an At-The-Market (ATM) Offering, allowing it to sell new shares directly into the stock market over time to provide flexible access to capital. The company projects revenue growth of 25-30% for the upcoming year, driven by increased adoption of its clinical trial matching services and data insights. Long-term agreements and liabilities extending into 2025 and beyond underscore a sustained operational and strategic execution plan aimed at achieving market leadership and eventual profitability.

7. Competitive Position

Tempus AI faces a highly competitive landscape, including established diagnostic companies, other AI-driven health tech firms, and pharmaceutical companies with in-house R&D capabilities. However, Tempus AI differentiates itself with its integrated, multimodal data platform, combining genomic, clinical, and imaging data with advanced AI analytics. Its aggressive strategy of acquiring specialized technologies (e.g., Deep 6 AI, Mpirik) and forming strategic partnerships (e.g., AstraZeneca, Ambry Genetics) expands its proprietary data assets, enhances its AI capabilities, and solidifies its market leadership in precision medicine. This approach creates a comprehensive ecosystem that is difficult for competitors to replicate.